Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Soligenix, Inc. is a late-stage biopharmaceutical company developing treatments for rare diseases and infectious threats. Its core segments focus on innovative therapies for cutaneous T-cell lymphoma, psoriasis, and inflammatory diseases, utilizing proprietary photodynamic and immune-modulating technologies. The company also advances vaccine platforms targeting biothreats like ricin, Ebola, and COVID-19, leveraging government grants and strategic partnerships to bring novel, targeted therapeutics and vaccines to global markets.
This description was generated via AI from an annual report. Updated about 1 year ago.